Menu
← Oncology Approval Tracker
FDA DECISION ·
Augtyro
repotrectinib · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children aged 12 years and older with NTRK fusion-positive solid tumors that are locally advanced, metastatic or would require highly morbid surgery, after progression on treatment or when no satisfactory alternative exists.
LAMPGEN ANALYSIS
Why it matters
Repotrectinib gained a tumor-agnostic NTRK indication after its earlier ROS1 lung cancer approval.
What research teams should watch
Distinguish a qualifying fusion from an isolated NTRK variant and document prior TRK-directed therapy and tumor assessment.
PRIMARY RECORDS